Back

SGLT2 inhibitors for HF treatments in 2022 - What do the guidelines tell us?

26 August 2022 (15:50 - 16:00)
Organised by:
Congress Presentation Part of: SGLT2 inhibitors in practice (part 1): what is the state of heart failure treatment in 2022? Chronic Heart Failure, Other Open Access ESC Congress 2022

About the speaker

Photo
Professor Giuseppe Rosano

St Georges Medical School, London (United Kingdom of Great Britain & Northern Ireland)

3 More presentations in this session

Presentation thumbnail
Welcome and introduction.
Professor J. Butler (Dallas, US)
Slides Video
Presentation thumbnail
What is the evidence for SGLT2 inhibitors in HF?
Professor I. Pina (Philadelphia, US)
Slides Video
Presentation thumbnail
Panel discussion.
Professor S. Anker (Berlin, DE)
Slides Video

Access the full session

Session thumbnail
SGLT2 inhibitors in practice (part 1): what is the state of heart failure treatment in 2022?
Video

The Event

Event poster

ESC Congress 2022

26 August 2022 15:50 CET
You may be interested in
thumbnail
Congress Session
SGLT2 inhibitors in practice (part 3): the case for early intervention in HFrEF
27 August 2022
thumbnail
Congress Presentation
Aggiornamento sullo scompenso cardiaco
26 August 2023
thumbnail
Congress Presentation
ESC recommendations for the use of SGLT2i, GLP-1 RA, mineralocorticoid receptor antagonists, and angiotensin receptor neprilysin inhibitor in the management of heart failure with mildly reduced or preserved ejection fraction
29 August 2026
thumbnail
Congress Presentation
Discussant review - A Pre-Specified Meta-Analysis of DELIVER and EMPEROR-Preserved.
27 August 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources